**Core Concept:** Double blinding is a crucial aspect of conducting randomized controlled trials (RCTs). It involves concealing the identity of the treatment allocation from both the patient and the investigator(s) to minimize bias. This ensures that the outcome assessment remains unbiased and reliable.

**Why the Correct Answer is Right:** In a double-blind study, neither the patient nor the researcher knows whether the participant is receiving the active treatment or the placebo (or control treatment). This helps eliminate subjective bias in evaluating the patient's response to the treatment. By reducing the influence of subjective perception, double blinding strengthens the internal validity of the study, making the results more generalizable and trustworthy.

**Why Each Wrong Option is Incorrect:**
A. Single blind trials (where the patient is unaware of the treatment) are not double-blind trials, which means that the researcher may not be blinded, leading to potential bias.
B. Single-blind trials (where only the patient is unaware of the treatment) are not double-blind trials, as the researcher(s) could have subjective bias.
C. Single-blind trials (where only the researcher is unaware of the treatment) are not double-blind trials, as the patient could potentially disclose the treatment allocation.
D. Single-blind trials (where neither the patient nor the researcher is blinded) are not double-blind trials, which increases the risk of bias and undermines the reliability and validity of the study results.

**Clinical Pearl:** Including double blinding in a clinical trial helps maintain internal validity and minimizes bias, ensuring the reliability and generalizability of the study findings. This crucial aspect of study design contributes to producing more accurate and trustworthy results.